Researchers Uncover Potential Achilles' Heel in Acute Myeloid Leukemia

Got story updates? Submit your updates here. ›

Researchers from Indiana University School of Medicine have made a breakthrough discovery in the fight against Acute Myeloid Leukemia (AML). Their study, published in the journal Leukemia, reveals that AML cells, particularly the treatment-resistant leukemia stem cells, are heavily dependent on a specific inflammatory signaling pathway known as Interleukin-1 (IL-1). By targeting this pathway with a novel compound called UR241-2, the team was able to significantly impair the ability of leukemia stem cells to form colonies and regenerate the cancer, while largely sparing healthy blood-forming cells.

Why it matters

AML is an aggressive form of blood cancer with a dismal 5-year survival rate of just 32.9%. The discovery of the IL-1 signaling pathway as a potential Achilles' heel in AML offers a glimmer of hope for more effective treatments. If further developed, therapies targeting this pathway could help reduce the risk of relapse and improve long-term prognosis for AML patients.

The details

The researchers employed genetic techniques to dampen IL-1 signaling in human AML cells, which resulted in a drastic reduction in the cells' ability to form colonies and regenerate the leukemia. The team then developed a novel compound, UR241-2, designed to block the key proteins in the IL-1 pathway. In preclinical models, UR241-2 not only impaired leukemia stem cells but also largely spared healthy blood-forming cells, significantly reducing leukemia levels in mice.

• The study was published in the journal Leukemia in 2026.

What they’re saying

What’s next

The researchers are now focused on further developing UR241-2 and exploring the potential of targeting the IL-1 signaling pathway as part of a multi-pronged approach to treating AML. The compound will need to undergo rigorous clinical trials before it can be considered for approval and use in patients.